Loading...

COYA COYA THERAPEUTICS INC US FDA Inspections 8-K Filing

CY T

CY

COYA THERAPEUTICS INC

(COYA)

2025 8-K

Summary

Summary

Stock Offering Launch

Milestone Payment

Clinical Trials

Clinical Trials

Earnings Releases

Financial Results

Quarterly Results

Director Resignation

Management Changes

Clinical Trial Results

Management Change

Quarterly Results

Other Special Situation

Agreement Amendment

Securities Purchase Agreement

Earnings Reports

Results of Operations and F...

Quantitative Data

Development and License Agr...

Results of Operations and F...

Earnings Report

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Earnings Reports

Earnings Reports

License Agreement with Dr. ...

Conference Call for ALS Cli...

Banking Relationship

Equity Compensation Grants

External Links:

On June 30, 2025, Coya Therapeutics, Inc. re-submitted its Investigational New Drug Application to the FDA to initiate a Phase 2 study for treating Amyotrophic Lateral Sclerosis (ALS), following a request for additional data from July 14, 2024.

AI Assistant

COYA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.